unity biotechnology publicly traded american biotechnology company develops drugs target senescent companys products development include targets bclxl mechanism eliminate senescent cells agerelated eye diseases phase clinical trials diabetic macular edema october july company reported positive results phase company reported april results phase study demonstrating single injection resulted statistically significant clinically meaningful improvement vision also include ubx preclinical product targeting ophthalmologic products senolytic medicines may company went public nasdaq exchange raising million market capitalization unity biotechnology shares dropped august company reported disappointing results clinical trial involving lead drug candidate patients moderatetosevere painful united states corporation company article stub help wikipedia expanding ithttpsenwikipediaorgwikiunitybiotechnology